Inovio Pharmaceuticals Under Legal Scrutiny Over Securities Fraud Allegations and BLA Delays

Inovio Pharmaceuticals Faces Legal Challenges over Securities Allegations

Inovio Pharmaceuticals, a biotechnology company focused on developing DNA medicines, experiences significant legal pressure as investigations into potential securities fraud unfold. Faruqi & Faruqi, LLP, a respected national securities law firm, is scrutinizing claims related to investments made in Inovio between October 10, 2023, and December 26, 2025. This investigation centers on allegations that Inovio and its executives may have violated federal securities laws through misleading statements and critical information omissions that could have influenced investor decisions.

The core focus of these allegations revolves around the manufacturing deficiencies associated with Inovio's CELLECTRA device, which is pivotal for delivering the company’s innovative therapies. Investigators assert that these deficiencies could prevent Inovio from meeting the critical deadlines for the Biologics License Application (BLA) for its treatment, INO-3107. Initially projected for submission to the FDA by late 2024, the timeline now appears uncertain. Furthermore, the investigation raises questions regarding the adequacy of Inovio’s data supporting claims about the BLA's eligibility for accelerated approval, putting into doubt earlier assumptions regarding regulatory and commercial expectations of the drug.

Moreover, following the pressing scrutiny, the FDA accepted the BLA for INO-3107 on December 29, 2025, but notably marked the review as “standard” rather than “accelerated.” This classification indicates that Inovio may not have provided sufficient data to merit an expedited review process, potentially impacting the drug’s market introduction timeline and overall investor outlook. As the investigation continues, affected investors are encouraged to reach out to Faruqi & Faruqi's partner James (Josh) Wilson to discuss claiming lead plaintiff status in the anticipated class action, with an application deadline set for April 7, 2026.

Inovio Pharmaceuticals, which has focused on pioneering DNA-based immunotherapies since its founding in 1995, now finds itself at a critical juncture that could affect its operational viability and credibility in the competitive biotech landscape. With a strong history of recovering losses for investors, Faruqi & Faruqi highlights the seriousness of the situation, revealing the intricate balance biotechnology firms must maintain between innovation and regulatory compliance. Investors and stakeholders closely monitor Inovio’s strategic responses as this complex legal scenario unfolds.